InMed Pharmaceuticals Completes Reverse Merger With Mentari, Renames Itself Mentari Therapeutics
InMed Pharmaceuticals closed its merger with private Mentari Therapeutics on Nov. 6, 2026, leaving former InMed holders with about 1% of the combined company, which renamed itself Mentari Therapeutics and now trades as MTRI.
What happened
InMed Pharmaceuticals Inc. closed its previously announced business combination with private Delaware company Mentari Therapeutics, Inc. on Nov. 6, 2026, according to an 8-K filed with the SEC on Nov. 10. The company has changed its name to Mentari Therapeutics, Inc. and its common stock now trades on the Nasdaq Capital Market under the ticker MTRI, the filing states.
The transaction was structured as a reverse merger. InMed's wholly owned subsidiary merged into Mentari, which became a wholly owned subsidiary, and Mentari then merged into a second InMed subsidiary that survived as 'Mentari Therapeutics Operating Company LLC.'
Under the exchange ratio in the merger agreement, Mentari holders received 0.20065 shares of the combined company for each Mentari share, after adjusting for a 1-for-10 reverse stock split InMed completed on Nov. 4, 2026. InMed also redomesticated from British Columbia, Canada, to Nevada as part of the closing.
After the merger and a concurrent private financing, former InMed securityholders own about 1.0% of the combined company on a fully diluted basis, while Mentari securityholders, including buyers in the financing, own about 99.0%, the filing says.
The financing
Immediately before the merger, Mentari sold 215,042,178 shares of common stock and 7,317,328 pre-funded warrants to institutional and accredited investors for about $490.0 million in aggregate. That figure includes $52.7 million of principal and accrued interest on convertible notes that were contributed as consideration rather than paid in cash.
The pre-funded warrants carry an exercise price of $0.0001 per share and do not expire. They are a way for investors to pay nearly the full purchase price upfront while deferring the formal exercise of the warrant, which can matter for ownership thresholds. Holders cannot exercise them if doing so would push their beneficial ownership above 19.99%, subject to adjustment on 61 days' notice.
The filing does not state why Mentari raised this amount or what the proceeds will fund. It describes the pricing formula: the first $290.0 million of commitments were priced off a $125.0 million valuation for Mentari, and an additional $200.0 million was priced at 152.8% of that per-share price.
Market reaction
The stock closed at $12.20 on the event date, down 23.75% from the prior close of $16.00, according to the price data. Volume was 57,300 shares, about 6.6 times the average volume of 8,671.
The sources provided do not explain the price move. Because former InMed holders now own about 1% of the combined company and the share count changed substantially through the merger and the $490 million financing, the closing price is not directly comparable to the pre-merger price without accounting for those changes.
What this means
The 8-K is a current report that public companies must file with the SEC within four business days of certain material events. This one covers the merger agreement (Item 1.01), completion of the acquisition (Item 2.01), the change in control and the new board and officers (Items 5.01 and 5.02), changes to the charter and bylaws (Items 5.03 and 5.05), and the unregistered sale of equity in the financing (Item 3.02).
A reverse merger is a path to becoming public without an initial public offering. A private company merges into a public shell, and the private company's owners end up with most of the combined company. The roughly 1%/99% split here shows the former InMed shareholders were substantially diluted relative to Mentari's owners and the new investors.
The reverse stock split and the change of ticker from INM to MTRI matter for anyone looking up the stock: the old quote is not the same security, and each pre-split InMed share became one-tenth of a share before the merger exchange. The 180-day lock-up agreements mean certain Mentari executives, directors and stockholders have agreed not to sell their shares for six months after the closing, which limits near-term supply but says nothing about the company's prospects.
The filing does not describe Mentari's business, revenue or pipeline, and it does not give a reason for the merger beyond the transaction terms. InMed's most recent annual revenue was $4.94 million for the period ending June 30, 2025. What happens next mechanically is that the combined company will report as Mentari Therapeutics, and its next quarterly filing will be the first to include Mentari's operations.
Sources
- Daily price and volume history
- 8-K filed 2026-11-10
- SEC XBRL financial data
Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.